Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REL-P11
- Development stage
- Unknown
- Lead developer
- Relmada Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
REL-P11 is a proprietary, low-dose, modified-release oral formulation of psilocybin developed by Relmada Therapeutics under license from Arbormentis. It is being investigated primarily for the treatment of metabolic diseases, including obesity and metabolic syndrome. Preclinical studies in rodents demonstrated that REL-P11 improved multiple metabolic parameters without detrimental central nervous system effects. The drug leverages the neuroplastogen effects of psilocybin, which may have potential to ameliorate neurodegenerative conditions as well. As of late 2024 and early 2025, REL-P11 has completed Phase 1 clinical trials evaluating safety and pharmacokinetics in obese and normal weight subjects; however, further development is being re-evaluated due to strategic prioritization within Relmada[1][3][4][5][6][7][8].
- Brand names
- REL-P11REL-P-11REL-P 11
- Other names
- psilocybin (as the active ingredient)
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)ABC family (ATP-binding cassette transporter family)5-HT2 (5-HT2 receptor family)
Beyond the preview
Go deeper on REL-P11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REL-P11.